Suppression of angiogenesis and tumor growth in vitro and in vivo using an anti-angiopoietin-2 single-chain antibody

Experimental and Therapeutic Medicine

Volumn 7, Issue 3, 2014, Pages 543-552

  Zhang, Zhong Lin ^a   Zhang, Ji Fa ^b   Yuan, Yu Feng ^a   He, Yue Ming ^a   Liu, Quan Yan ^a   Mao, Xiao Wen ^a   Ai, Yong Biao ^a   Liu, Zhi Su ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b Department of Orthopedic Surgery   (China)

Author keywords

Angiopoietin 2; Liver tumor; Neovascularization; Phage display peptide library; Single chain antibody

Indexed keywords

EID: 84892968694     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1476     Document Type: Article

References (47)

1. Pisani P, Parkin DM, Bray F and Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83: 18-29, 1999.
2. D'Amato RJ, Loughnan MS, Flynn E and Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085, 1994.
3. Farris AB III, Dursun N, Dhanasekaran R, Coban I, McIntosh EB, Adsay NV and Kim HS: Tumoral and angiogenesis factors in hepatocellular carcinoma after locoregional therapy. Pathol Res Pract 208: 15-21, 2012.
4. Chao Y, Li CP, Chau GY, Chen CP, King KL, Lui WY, Yen SH, Chang FY, Chan WK and Lee SD: Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 10: 355-362, 2003.
5. Jeng KS, Sheen IS, Wang YC, Gu SL, Chu CM, Shih SC, Wang PC, Chang WH and Wang HY: Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study. World J Gastroenterol 10: 643-646, 2004.
6. Poon RT, Ho JW, Tong CS, Lau C, Ng IO and Fan ST: Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 91: 1354-1360, 2004.
7. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186, 1971.
8. Eichholz A, Merchant S and Gaya AM: Anti-angiogenesis therapies: their potential in cancer management. Onco Targets Ther 3: 69-82, 2010.
9. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX and Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434, 2003.
10. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD and Vassel A: A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30 (5 Suppl 16): 117-124, 2003.
11. Mayer RJ: Two steps forward in the treatment of colorectal cancer. N Engl J Med 350: 2406-2408, 2004.
12. Desplancq D, Rinaldi AS, Stoessel A, Sibler AP, Busso D, Oulad-Abdelghani M, Van Regenmortel MH and Weiss E: Single-chain Fv fragment antibodies selected from an intrabody library as effective mono-or bivalent reagents for invitro protein detection. J Immunol Methods 369: 42-50, 2011.
13. Yamaguchi R, Yano H, Nakashima Y, Ogasawara S, Higaki K, Akiba J, Hicklin DJ and Kojiro M: Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep 7: 725-729, 2000.
14. Ochiumi T, Tanaka S, Oka S, Hiyama T, Ito M, Kitadai Y, Haruma K and Chayama K: Clinical significance of angiopoietin-2 expression at the deepest invasive tumor site of advanced colorectal carcinoma. Int J Oncol 24: 539-547, 2004.
15. Sun XD, Liu XE, Wu JM, Cai XJ, Mou YP and Li JD: Expression and significance of angiopoietin-2 in gastric cancer. World J Gastroenterol 10: 1382-1385, 2004.
16. Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G, O'Brien-Jenkins A, Randall TC, Rubin SC and Coukos G: Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 63: 3403-3412, 2003.
17. Sfiligoi C, de Luca A, Cascone I, Sorbello V, Fuso L, Ponzone R, Biglia N, Audero E, Arisio R, Bussolino F, Sismondi P and DeBortoli M: Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer 103: 466-474, 2003.
18. Glade Bender J, Cooney EM, Kandel JJ and Yamashiro DJ: Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Updat 7: 289-300, 2004.
19. Wong MP, Chan SY, Fu KH, Leung SY, Cheung N, Yuen ST and Chung LP: The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas. Lung Cancer 29: 11-22, 2000.
20. Zhang ZL, Liu ZS and Sun Q: Significance of angiopoietins, Tie2 and vascular endothelial growth factor in the angiogenesis and development of hepatocellular carcinoma. World J Gastroenterol 12: 4241-4245, 2006.
21. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN and Yancopoulos GD: Angiopoietin-2, a natural antagonist for Tie2 that disrupts invivo angiogenesis. Science 277: 55-60, 1997.
22. Dai H, Gao H, Zhao X, Dai L, Zhang X, Xiao N, Zhao R and Hemmingsen SM: Construction and characterization of a novel recombinant single-chain variable fragment antibody against White Spot Syndrome Virus from shrimp. J Immunol Methods 279: 267-275, 2003.
23. Barbas CF III, Burton DR, Scott JK and Silverman GJ (eds): Phage Display: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 2001.
24. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991.
25. Gale NW and Yancopoulos GD: Growth factors acting via endothelia cell-spcific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 13: 1055-1066, 1999.
26. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC and Yancopoulos GD: Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87: 1161-1169, 1996.
27. Saharinen P, Bry M and Alitalo K: How do angiopoietins Tie in with vascular endothelial growth factors? Curr Opin Hematol 17: 198-205, 2010.
28. Pham VN, Roman BL and Weinstein BM: Isolation and expression analysis of three zebrafish angiopoietin genes. Dev Dyn 221: 470-474, 2001.
29. Hata K, Udagawa J, Fujiwaki R, Nakayama K, Otani H and Miyazaki K: Expression of angiopoietin-1, angiopoietin-2, and Tie2 genes in normal ovary with corpus luteum and in ovarian cancer. Oncology 62: 340-348, 2002.
30. Mitsuhashi N, Shimizu H, Ohtsuka M, Wakabayashi Y, Ito H, Kimura F, Yoshidome H, Kato A, Nukui Y and Miyazaki M: Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 37: 1105-1113, 2003.
31. Sugimachi K, Tanaka S, Taguchi K, Aishima S, Shimada M and Tsuneyoshi M: Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma. J Clin Pathol 56: 854-860, 2003.
32. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN and Yancopoulos GD: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171-1180, 1996.
33. Teichert-Kuliszewska K, Maisonpierre PC, Jones N, Campbell AI, Master Z, Bendeck MP, Alitalo K, Dumont DJ, Yancopoulos GD and Stewart DJ: Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res 49: 659-670, 2001.
34. Wang J, Wu K, Zhang D, Tang H, Xie H, Hong L, Pan Y, Lan M, Hu S, Ning X and Fan D: Expression and clinical significances of angiopoietin-1,-2 and Tie2 in human gastric cancer. Biochem Biophy Res Commun 337: 386-393, 2005.
35. Nakayama T, Hatachi G, Wen CY, Yoshizaki A, Yamazumi K, Niino D and Sekine I: Expression and significance of Tie-1 and Tie-2 receptors, and angiopoietins-1, 2 and 4 in colorectal adenocarcinoma: Immunohistochemical analysis and correlation with clinicopathological factors. World J Gastroenterol 11: 964-969, 2005.
36. Wada H, Nagano H, Yamamoto H, Yang Y, Kondo M, Ota H, Nakamura M, Yoshioka S, Kato H, Damdinsuren B, Tang D, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Nakamori S, Sakon M, Dono K, Wakasa K and Monden M: Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int 26: 414-423, 2006.
37. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62, 2005.
38. Smith GP: Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228: 1315-1317, 1985.
39. Smith GP and Petrenko VA: Phage Display. Chem Rev 97: 391-410, 1997.
40. Bratkovic T: Progress in phage display. Cell Mol Life Sci 67: 749-767, 2010.
41. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotný J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R, et al: Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 85: 5879-5883, 1988.
42. Rao Y, Zhong L, Liao T, Jin S, Wang Y, Song B, Li J, Zhang X, Hemmingsen SM, Xu Y and Dai H: Novel recombinant monoclonal antibodies for vitellogenin assays in cyprinid fish species. Dis Aquat Organ 93: 83-91, 2010.
43. Lobov IB, Brooks PC and Lang RA: Angiopoietin-2 displays VEGF-dependent modulations of capilliary structure and endothelial cell survival invivo. Proc Natl Acad Sci USA 99: 11205-11210, 2002.
44. Ji Y, Wang Z, Li Z, Li K, Le X and Zhang T: Angiotensin II induces angiogenic factors production partly via AT1/JAK2/STAT3/SOCS3 signaling pathway in MHCC97H cells. Cell Physiol Biochem 29: 863-874, 2012.
45. Imai N, Hashimoto T, Kihara M, Yoshida S, Kawana I, Yazawa T, Kitamura H and Umemura S: Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis. Lab Invest 87: 189-198, 2007.
46. White RR, Shan S, Rusconi CP, Shetty G, Dewhirst MW, Kontos CD and Sullenge BA: Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Aead Sci USA 100: 5028-5033, 2003.
47. Li Y, Tang Y, Ye L, Liu B, Liu K, Chen J and Xue Q: Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through invivo selection and screening for metastisis-related genes through cDNA microarray. J Cancer Res Clin Oncol 129: 43-51, 2003.